Additional Treatments to the Local Tumour for Metastatic Prostate Cancer: Assessment of Novel Treatment Algorithms (IP2-ATLANTA)
Local Cytoreductive Treatments for Men With Newly Diagnosed Metastatic Prostate Cancer in Addition to Standard of Care Treatment
Sponsor: Imperial College London
Listed as NCT03763253, this PHASE2 trial focuses on Metastatic Prostate Cancer and Prostate Cancer and remains ongoing. Sponsored by Imperial College London, it has been updated 11 times since 2019, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Active Not Recruiting PHASE2
-
Mar 2025 — Sep 2025 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Sep 2024 — Mar 2025 [monthly]
Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2
-
Sep 2023 — Jul 2024 [monthly]
Recruiting PHASE2
▶ Show 6 earlier versions
-
Mar 2021 — Sep 2023 [monthly]
Recruiting PHASE2
-
Jan 2021 — Mar 2021 [monthly]
Recruiting PHASE2
-
Sep 2020 — Jan 2021 [monthly]
Recruiting PHASE2
-
Aug 2019 — Sep 2020 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Mar 2019 — Aug 2019 [monthly]
Not Yet Recruiting PHASE2
-
Jan 2019 — Mar 2019 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Imperial College London
- Wellcome Trust
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Birkenhead, United Kingdom , Bodelwyddan, United Kingdom , Dartford, United Kingdom , Exeter, United Kingdom , High Wycombe, United Kingdom , Isleworth, United Kingdom , Kings Lynn, United Kingdom , London, United Kingdom , Metropolitan Borough of Wirral, United Kingdom , Newcastle, United Kingdom and 5 more locations